BioPharma Resources

Investigational drug · Phase 3

Remternetug

Also called: LY3372993

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Alzheimer's Disease.

Phase 3

Last checked: Nov 19, 2026Latest source record: Oct 7, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

1

1 still active

All registered trials

6

Any phase or sponsor naming "Remternetug"

First trial start

2024

Oct 24, 2024

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "Remternetug", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Alzheimer's Disease

Approved drugs for the same conditions: Alzheimer's disease · Neurology

Largest trials

Live from ClinicalTrials.gov: studies naming "Remternetug" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 8 on PubMed

Also in development for Alzheimer's Disease

  • KarX-ECBMS-986519, Xanomeline Enteric-coatedPhase 39 trials

    Bristol Myers Squibb · Alzheimer Disease, Alzheimer's Disease, Irritability Associated With Autism Spectrum Disorder

  • TrontinemabRO7126209, RG6102Phase 34 trials

    Roche (Genentech) · Alzheimers Disease, Alzheimer's Disease

  • [18F]-APN-1607Phase 32 trials

    JYAMS PET Research & Development Limited · Alzheimer's Disease, Subjects With Mild Cognitive Impairment (MCI) of AD, Alzheimer's Disease (AD) Dementia

  • RO7568282Phase 22 trials

    Roche (Genentech) · Parkinson's Disease, Alzheimer's Disease

  • VHB937Phase 22 trials

    Novartis · Amyotrophic Lateral Sclerosis (ALS), Alzheimer's Disease

  • ABBV-1758Phase 21 trial

    AbbVie · Alzheimer's Disease

  • E2814Phase 21 trial

    Eisai · Alzheimer's Disease

  • GSK4527226Phase 21 trial

    GSK · Alzheimer's Disease

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Eli Lilly.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.